MARKET

IMMP

IMMP

Immutep
NASDAQ
2.060
+0.070
+3.52%
After Hours: 1.970 -0.09 -4.37% 18:32 12/04 EST
OPEN
1.970
PREV CLOSE
1.990
HIGH
2.150
LOW
1.970
VOLUME
228.18K
TURNOVER
0
52 WEEK HIGH
3.900
52 WEEK LOW
1.500
MARKET CAP
244.90M
P/E (TTM)
-6.9104
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IMMP last week (1127-1201)?
Weekly Report · 15h ago
Weekly Report: what happened at IMMP last week (1120-1124)?
Weekly Report · 11/27 10:21
Immutep Announces Site Expansion For INSIGHT-003 Phase I Trial
Immutep is developing novel lag-3 immunotherapies for cancer and autoimmune disease. The insight-003 trial has been expanded to four sites across germany. The study is evaluating eftilagimod alpha in combination with anti-pd-1 and chemotherapy for non-small cell lung cancer.
Benzinga · 11/22 13:03
Weekly Report: what happened at IMMP last week (1113-1117)?
Weekly Report · 11/20 10:19
Weekly Report: what happened at IMMP last week (1106-1110)?
Weekly Report · 11/13 10:15
Immutep: Report of foreign issuer
Press release · 11/10 00:07
Positive Biomarker Data and Trial Advancements Boost Immutep’s Buy Rating: An Analysis of Eftilagimod Alpha’s Potential
TipRanks · 11/08 05:49
Immutep: Report of foreign issuer
Press release · 11/06 23:01
More
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. The Company has three clinical and one pre-clinical LAG-3-related product candidates under development, including two antibodies for modulating immune responses in cancer and autoimmunity. Its lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), an antigen-presenting cell (APC) activator, which is being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for various cancer indications, including IMP761, which is preclinical immunotherapy for autoimmune disease; LAG525 or leramilimab (IMP701), which is immunotherapy for solid tumors, blood cancer and breast cancer, and GSK‘781 (IMP731), which is immunotherapy in autoimmune diseases. Its subsidiaries include Immutep USA Inc, Immutep GmbH, Immutep Australia Pty Ltd and Immutep S.A.S.

Webull offers Immutep Ltd stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.